Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1181INDUSTRY 351NIH 113NETWORK 48OTHER_GOV 33UNKNOWN 11FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Recurrence 1Neoplasms 1Neoplasm Metastasis 1Head and Neck Neoplasms 1Carcinoma, Squamous Cell 1

Interventions

Exercise 6pembrolizumab 5enzalutamide 4Docetaxel 4Colonoscopy 4Celecoxib 4sargramostim 3apalutamide 3Prednisone 3Methods 3Leuprolide 3Itraconazole 3Imiquimod 3Granulocyte-Macrophage Colony-Stimulating Factor 3Golytely 3Cryotherapy 3Abiraterone Acetate 32-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 3abiraterone 2Yoga 2Topotecan 2Testosterone 2Tablets 2Simvastatin 2Radiosurgery 2Palliative Care 2Midazolam 2Gelatin 2Decision Support Techniques 2Collagenases 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
FED × Oxaliplatin × Clear all
NCT00557206 2013-11-05

Oxaliplatin and Docetaxel for Recurrent or Metastatic Head and Neck Cancer

Minneapolis Veterans Affairs Medical Center

Phase 2 Terminated
35 enrolled
Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡